Compare ALEMBIC with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs IPCA LABS - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC IPCA LABS ALEMBIC/
IPCA LABS
 
P/E (TTM) x 57.8 26.5 218.1% View Chart
P/BV x 5.0 8.3 60.3% View Chart
Dividend Yield % 0.2 0.1 139.5%  

Financials

 ALEMBIC   IPCA LABS
EQUITY SHARE DATA
    ALEMBIC
Mar-18
IPCA LABS
Mar-19
ALEMBIC/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs721,042 6.9%   
Low Rs34590 5.7%   
Sales per share (Unadj.) Rs4.7298.6 1.6%  
Earnings per share (Unadj.) Rs6.135.0 17.4%  
Cash flow per share (Unadj.) Rs6.249.4 12.6%  
Dividends per share (Unadj.) Rs0.203.00 6.7%  
Dividend yield (eoy) %0.40.4 102.7%  
Book value per share (Unadj.) Rs40.7247.1 16.5%  
Shares outstanding (eoy) m267.03126.35 211.3%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x11.32.7 412.2%   
Avg P/E ratio x8.723.3 37.2%  
P/CF ratio (eoy) x8.516.5 51.4%  
Price / Book Value ratio x1.33.3 39.4%  
Dividend payout %3.38.6 38.2%   
Avg Mkt Cap Rs m14,139103,108 13.7%   
No. of employees `000NA13.4 0.0%   
Total wages/salary Rs m2077,874 2.6%   
Avg. sales/employee Rs ThNM2,807.0-  
Avg. wages/employee Rs ThNM585.8-  
Avg. net profit/employee Rs ThNM329.0-  
INCOME DATA
Net Sales Rs m1,25537,732 3.3%  
Other income Rs m370577 64.2%   
Total revenues Rs m1,62538,309 4.2%   
Gross profit Rs m1116,901 1.6%  
Depreciation Rs m381,824 2.1%   
Interest Rs m2189 0.9%   
Profit before tax Rs m4425,465 8.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m241,042 2.3%   
Profit after tax Rs m1,6304,422 36.9%  
Gross profit margin %8.918.3 48.4%  
Effective tax rate %5.419.1 28.4%   
Net profit margin %129.811.7 1,107.9%  
BALANCE SHEET DATA
Current assets Rs m1,86723,778 7.9%   
Current liabilities Rs m59110,975 5.4%   
Net working cap to sales %101.633.9 299.6%  
Current ratio x3.22.2 145.8%  
Inventory Days Days94104 90.8%  
Debtors Days Days7466 111.6%  
Net fixed assets Rs m1,79120,368 8.8%   
Share capital Rs m534253 211.4%   
"Free" reserves Rs m10,32430,971 33.3%   
Net worth Rs m10,85831,224 34.8%   
Long term debt Rs m411,409 2.9%   
Total assets Rs m11,59145,507 25.5%  
Interest coverage x260.930.0 870.8%   
Debt to equity ratio x00 8.4%  
Sales to assets ratio x0.10.8 13.1%   
Return on assets %14.110.1 138.9%  
Return on equity %15.014.2 106.0%  
Return on capital %15.217.3 87.7%  
Exports to sales %1.545.9 3.4%   
Imports to sales %21.016.6 126.3%   
Exports (fob) Rs m1917,308 0.1%   
Imports (cif) Rs m2636,266 4.2%   
Fx inflow Rs m1917,308 0.1%   
Fx outflow Rs m2646,266 4.2%   
Net fx Rs m-24411,042 -2.2%   
CASH FLOW
From Operations Rs m2364,923 4.8%  
From Investments Rs m-224-1,563 14.3%  
From Financial Activity Rs m-27-1,832 1.5%  
Net Cashflow Rs m-151,528 -1.0%  

Share Holding

Indian Promoters % 64.0 45.9 139.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.4 1.8%  
FIIs % 9.7 25.3 38.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.4 150.0%  
Shareholders   54,701 36,892 148.3%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC  ASTRAZENECA PHARMA  BIOCON   

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 22, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS